Divi’s Laboratories witnessed a remarkable surge in its stock price, jumping 4% following the announcement of its Q3 results. As of 1:35 PM, the shares were trading 3.83% higher at Rs 5,833.55.
The pharmaceutical giant reported a net profit of ₹589 crore, reflecting an impressive 65% year-on-year (YoY) growth from ₹358 crore in the same quarter last year. This stellar performance was primarily driven by robust revenue growth and efficient cost management.
The company’s revenue from operations reached ₹2,319 crore, marking a 25% YoY increase from ₹1,855 crore in Q3 FY24. However, sequentially, revenue saw a minor dip compared to ₹2,338 crore in Q2 FY25. Including other income of ₹82 crore, the total income for the quarter stood at ₹2,401 crore, significantly higher than ₹1,950 crore in the year-ago period.
Despite an increase in total expenses to ₹1,675 crore from ₹1,461 crore, mainly due to higher material costs, Divi’s Laboratories demonstrated strong operational efficiency. The profit before tax (PBT) surged to ₹726 crore from ₹489 crore in Q3 FY24, underscoring the company’s resilient business model. A reduced tax expense of ₹137 crore further boosted the bottom line, leading to a strong net profit.
For the nine months ended December 31, 2024, the company reported revenue of ₹6,775 crore, compared to ₹5,542 crore in the previous year, while net profit rose to ₹1,529 crore from ₹1,062 crore.
Divi’s Laboratories shares opened today at ₹5,619.00, reaching a high of ₹5,880.00 and a low of ₹5,471.00. The stock’s 52-week high stands at ₹6,285.45, while its low is ₹3,350.00.
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
